Swedish biotechnology company Active Biotech AB (STO: ACTI) said on Monday that the US Patent Office (USPTO) has decided to grant Active Biotech's patent related to use of laquinimod as a treatment for eye diseases associated with excessive vascularisation.
The patent is expected to be issued on 25 October 2022 under patent number 11,478,465, providing protection and market exclusivity in this field of use until 2040.
Specifically, Active Biotech's new patent covers the medical use of des-ethyl laquinimod for treatment of sight-threatening eye disorders such as age-related macular degeneration (wet AMD), corneal neovascularisation, choroidal neovascularisation, proliferative diabetic retinopathy, retinopathy of prematurity and ischemic retinopathy.
Active Biotech already has a European patent for the use of laquinimod in eye diseases associated with excessive vascularisation.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes